BRAF mutations are associated with increased iron regulatory protein-2 expression in colorectal tumorigenesis

Cancer Science

Volumn 108, Issue 6, 2017, Pages 1135-1143

  Horniblow, Richard D ^a   Bedford, Matthew ^a   Hollingworth, Robert ^a   Evans, Sarah ^a   Sutton, Emily ^a   Lal, Neeraj ^a   Beggs, Andrew ^a   Iqbal, Tariq H ^a   Tselepis, Chris ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

BRAF; colorectal cancer; iron; iron regulatory protein 2; trametinib

Indexed keywords

APC PROTEIN; B RAF KINASE; CD71 ANTIGEN; EPIDERMAL GROWTH FACTOR; FERRITIN; IRON REGULATORY PROTEIN 2; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SMALL INTERFERING RNA; TRAMETINIB; BRAF PROTEIN, HUMAN; IRON; IRP2 PROTEIN, HUMAN; TRANSFERRIN RECEPTOR;

ARTICLE; CARCINOGENESIS; CLINICAL ASSESSMENT; COLON MUCOSA; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; ENZYME INHIBITION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRON METABOLISM; IRON TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CACO-2 CELL LINE; COLORECTAL TUMOR; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

CACO-2 CELLS; CARCINOGENESIS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FERRITINS; HCT116 CELLS; HT29 CELLS; HUMANS; IRON; IRON REGULATORY PROTEIN 2; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, TRANSFERRIN; RNA, SMALL INTERFERING;

EID: 85020093666     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13234     Document Type: Article

References (33)

1. Brookes MJ, Hughes S, Turner FE et al. Modulation of iron transport proteins in human colorectal carcinogenesis. Gut 2006; 55: 1449–60.
2. Miller LD, Coffman LG, Chou JW et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 2011; 71: 6728–37.
3. Pinnix ZK, Miller LD, Wang W et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010; 2: 43–56.
4. Wang W, Deng Z, Hatcher H et al. IRP2 regulates breast tumor growth. Cancer Res 2014; 74: 497–507.
5. Ward DG, Roberts K, Brookes MJ et al. Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol 2008; 14: 1339–45.
6. Torti SV, Torti FM. Iron and cancer: More ore to be mined. Nat Rev Cancer 2013; 13: 342–55.
7. Schonberg DL, Miller TE, Wu Q et al. Preferential iron trafficking characterizes glioblastoma stem-like cells. Cancer Cell 2015; 28: 441–55.
8. Brookes M, Boult J, Roberts K et al. A role for iron in Wnt signalling. Oncogene 2008; 27: 966–75.
9. Radulescu S, Brookes MJ, Salgueiro P et al. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep 2012; 2: 270–82.
10. Song S, Christova T, Perusini S et al. Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res 2011; 71: 7628–39.
11. Yu Y, Gutierrez E, Kovacevic Z et al. Iron chelators for the treatment of cancer. Curr Med Chem 2012; 19: 2689–702.
12. Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 2008; 28: 197–213.
13. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2006; 2: 406–14.
14. Wu K-J, Polack A, Dalla-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science 1999; 283: 676–9.
15. O'Donnell KA, Yu D, Zeller KI et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol 2006; 26: 2373–86.
16. Maffettone C, Chen G, Drozdov I et al. Tumorigenic properties of iron regulatory protein 2 (IRP2) mediated by its specific 73-amino acids insert. PLoS ONE 2010; 5: e10163.
17. Horniblow RD, Dowle M, Iqbal TH et al. Alginate-iron speciation and its effect on in vitro cellular iron metabolism. PLoS ONE 2015; 10: e0138240.
18. Boult JKR, Tanière P, Hallissey MT et al. Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network. Br J Cancer 2008; 98: 1985–92.
19. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401–4.
20. Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: 11.
21. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–7.
22. Dry JR, Pavey S, Pratilas CA et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010; 70: 2264–73.
23. Ahmed D, Eide P, Eilertsen I et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013; 2: e71.
24. He T-C, Sparks AB, Rago C et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509–12.
25. Hanson ES, Foot LM, Leibold EA. Hypoxia post-translationally activates iron-regulatory protein 2. J Biol Chem 1999; 274: 5047–52.
26. Goethals L, Debucquoy A, Perneel C et al. Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys 2006; 65: 246–54.
27. Sideris M, Adams K, Moorhead J et al. BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia. Anticancer Res 2015; 35: 2345–50.
28. Cabantchik ZI. Labile iron in cells and body fluids: Physiology, pathology, and pharmacology. Front Pharmacol 2014; 5: 45.
29. Louandre C, Ezzoukhry Z, Godin C et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer 2013; 133: 1732–42.
30. Lui GY, Kovacevic Z, Richardson V et al. Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget 2015; 6: 18748.
31. Wang J, Yin D, Xie C, et al. The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway. Oncotarget 2014; 5: 8478.
32. Dixon K, Lui G, Kovacevic Z et al. Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. Br J Cancer 2013; 108: 409–19.
33. Munoz P, Zavala G, Castillo K et al. Effect of iron on the activation of the MAPK/ERK pathway in PC12 neuroblastoma cells. Biol Res 2006; 39: 189–90.